- Home
- IVA vs INMB Comparison
IVA vs INMB Comparison
Compare IVA & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVA
- INMB
- Stock Information
- Founded
- IVA 2011
- INMB 2015
- Country
- IVA France
- INMB United States
- Employees
- IVA N/A
- INMB N/A
- Industry
- IVA Biotechnology: Pharmaceutical Preparations
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- IVA Health Care
- INMB Health Care
- Exchange
- IVA Nasdaq
- INMB Nasdaq
- Market Cap
- IVA 162.8M
- INMB 176.5M
- IPO Year
- IVA 2020
- INMB 2019
- Fundamental
- Price
- IVA $3.07
- INMB $7.27
- Analyst Decision
- IVA Strong Buy
- INMB Strong Buy
- Analyst Count
- IVA 5
- INMB 3
- Target Price
- IVA $12.40
- INMB $24.33
- AVG Volume (30 Days)
- IVA 10.0K
- INMB 269.3K
- Earning Date
- IVA 03-26-2025
- INMB 05-08-2025
- Dividend Yield
- IVA N/A
- INMB N/A
- EPS Growth
- IVA N/A
- INMB N/A
- EPS
- IVA N/A
- INMB N/A
- Revenue
- IVA $15,243,814.00
- INMB $14,000.00
- Revenue This Year
- IVA $18.05
- INMB N/A
- Revenue Next Year
- IVA $46.74
- INMB N/A
- P/E Ratio
- IVA N/A
- INMB N/A
- Revenue Growth
- IVA N/A
- INMB N/A
- 52 Week Low
- IVA $1.53
- INMB $4.32
- 52 Week High
- IVA $3.98
- INMB $12.72
- Technical
- Relative Strength Index (RSI)
- IVA 56.44
- INMB 43.21
- Support Level
- IVA $2.88
- INMB $7.07
- Resistance Level
- IVA $3.10
- INMB $8.16
- Average True Range (ATR)
- IVA 0.22
- INMB 0.67
- MACD
- IVA -0.00
- INMB -0.05
- Stochastic Oscillator
- IVA 48.03
- INMB 13.02
Stock Price Comparison Chart: IVA vs INMB
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.